Long-term biokinetics and radiation exposure of patients undergoing 14C-glycocholic acid and 14C-xylose breath tests.
(2007) In Cancer Biotherapy & Radiopharmaceuticals 22(6). p.762-771- Abstract
- The (14)C-glycocholic acid and (14)C-xylose breath tests are clinically used for the diagnosis of intestinal diseases, such as bacterial overgrowth in the small intestine. The two tests have in earlier studies been thoroughly evaluated regarding their clinical value, but due to the long physical half-life of (14)C and the limited biokinetic and dosimetric data, which are available for humans, several hospitals have been restrictive in their use. The aim of this study was to investigate the long-term biokinetics and dosimetry of the two (14)C compounds in patients and volunteers, using the highly sensitive accelerator mass spectrometry (AMS) technique. Eighteen (18) subjects were included, 9 for each compound. The (14)C content in samples... (More)
- The (14)C-glycocholic acid and (14)C-xylose breath tests are clinically used for the diagnosis of intestinal diseases, such as bacterial overgrowth in the small intestine. The two tests have in earlier studies been thoroughly evaluated regarding their clinical value, but due to the long physical half-life of (14)C and the limited biokinetic and dosimetric data, which are available for humans, several hospitals have been restrictive in their use. The aim of this study was to investigate the long-term biokinetics and dosimetry of the two (14)C compounds in patients and volunteers, using the highly sensitive accelerator mass spectrometry (AMS) technique. Eighteen (18) subjects were included, 9 for each compound. The (14)C content in samples from exhaled air, urine, and, for some subjects, also feces were analyzed with both liquid scintillation counting (LSC) and AMS. The results from the glycocholic acid study showed that, up to 1 year after the administration, 67%+/-6% (mean+/-standard deviation) of the administered activity was recovered in exhaled air, 2.4%+/-0.4% was found in urine, and 7.6% (1 subject) in feces. In the xylose study, the major part was found in the urine (66%+/-2%). A significant part was exhaled (28%+/-5%), and the result from an initial 72-hour stool collection from 2 of the subjects showed that the excretion by feces was insignificant. The absorbed dose to various organs and tissues and the effective dose were calculated by using biokinetic models, based on a combination of experimental data from the present study and from earlier reports. In the glycocholic acid study, the highest absorbed dose was received by the colon (1.2 mGy/MBq). In the xylose study, the adipose tissue received 0.8 mGy/MBq. The effective dose was estimated to 0.5 (glycocholic acid) and 0.07 mSv/MBq (xylose). Thus, from a radiation protection point of view, we see no need for restrictions in using the two (14)C-labeled radiopharmaceuticals on adults with the activities normally administered (0.07-0.4 MBq). (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1034923
- author
- Gunnarsson, Mikael LU ; Leide Svegborn, Sigrid LU ; Stenström, Kristina LU ; Skog, Göran LU ; Nilsson, Lars-Erik ; Thorsson, Ola LU ; Hellborg, Ragnar LU and Mattsson, Sören LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer Biotherapy & Radiopharmaceuticals
- volume
- 22
- issue
- 6
- pages
- 762 - 771
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- pmid:18158767
- wos:000252265700006
- scopus:37549061379
- pmid:18158767
- ISSN
- 1557-8852
- DOI
- 10.1089/cbr.2007.0350
- language
- English
- LU publication?
- yes
- id
- 2ef23623-af5b-4473-841d-631db3ba07a4 (old id 1034923)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18158767?dopt=Abstract
- date added to LUP
- 2016-04-04 09:36:49
- date last changed
- 2023-09-06 01:44:22
@article{2ef23623-af5b-4473-841d-631db3ba07a4,
abstract = {{The (14)C-glycocholic acid and (14)C-xylose breath tests are clinically used for the diagnosis of intestinal diseases, such as bacterial overgrowth in the small intestine. The two tests have in earlier studies been thoroughly evaluated regarding their clinical value, but due to the long physical half-life of (14)C and the limited biokinetic and dosimetric data, which are available for humans, several hospitals have been restrictive in their use. The aim of this study was to investigate the long-term biokinetics and dosimetry of the two (14)C compounds in patients and volunteers, using the highly sensitive accelerator mass spectrometry (AMS) technique. Eighteen (18) subjects were included, 9 for each compound. The (14)C content in samples from exhaled air, urine, and, for some subjects, also feces were analyzed with both liquid scintillation counting (LSC) and AMS. The results from the glycocholic acid study showed that, up to 1 year after the administration, 67%+/-6% (mean+/-standard deviation) of the administered activity was recovered in exhaled air, 2.4%+/-0.4% was found in urine, and 7.6% (1 subject) in feces. In the xylose study, the major part was found in the urine (66%+/-2%). A significant part was exhaled (28%+/-5%), and the result from an initial 72-hour stool collection from 2 of the subjects showed that the excretion by feces was insignificant. The absorbed dose to various organs and tissues and the effective dose were calculated by using biokinetic models, based on a combination of experimental data from the present study and from earlier reports. In the glycocholic acid study, the highest absorbed dose was received by the colon (1.2 mGy/MBq). In the xylose study, the adipose tissue received 0.8 mGy/MBq. The effective dose was estimated to 0.5 (glycocholic acid) and 0.07 mSv/MBq (xylose). Thus, from a radiation protection point of view, we see no need for restrictions in using the two (14)C-labeled radiopharmaceuticals on adults with the activities normally administered (0.07-0.4 MBq).}},
author = {{Gunnarsson, Mikael and Leide Svegborn, Sigrid and Stenström, Kristina and Skog, Göran and Nilsson, Lars-Erik and Thorsson, Ola and Hellborg, Ragnar and Mattsson, Sören}},
issn = {{1557-8852}},
language = {{eng}},
number = {{6}},
pages = {{762--771}},
publisher = {{Mary Ann Liebert, Inc.}},
series = {{Cancer Biotherapy & Radiopharmaceuticals}},
title = {{Long-term biokinetics and radiation exposure of patients undergoing 14C-glycocholic acid and 14C-xylose breath tests.}},
url = {{http://dx.doi.org/10.1089/cbr.2007.0350}},
doi = {{10.1089/cbr.2007.0350}},
volume = {{22}},
year = {{2007}},
}